Metastatic pancreatic and lung cancer patient in complete remission following immunotherapy: A case report and review of literature

doi:10.4251/wjgo.v16.i5.2233

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 5

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4372)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-4) series.

Item

Count

PDF

133

HTML

2560

Figures (1-4)

424

Sum=3117

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

309

Download

766

Sum=1075

May 15, 2024 (publication date) through Feb 20, 2026

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Report

World J Gastrointest Oncol. May 15, 2024; 16(5): 2233-2240
Published online May 15, 2024. doi: 10.4251/wjgo.v16.i5.2233

Metastatic pancreatic and lung cancer patient in complete remission following immunotherapy: A case report and review of literature

Joaquina Martínez-Galán, Cristina Jiménez-Luna, Isabel Rodriguez, Elisabeth Maza, Carlos García-Collado, Antonio Rodríguez-Fernández, Javier Luis López-Hidalgo, Octavio Caba

Joaquina Martínez-Galán, Isabel Rodriguez, Elisabeth Maza, Department of Medical Oncology, Virgen de las Nieves University Hospital, Granada 18014, Spain

Joaquina Martínez-Galán, Cristina Jiménez-Luna, Isabel Rodriguez, Elisabeth Maza, Carlos García-Collado, Antonio Rodríguez-Fernández, Javier Luis López-Hidalgo, Octavio Caba, Instituto de Investigación Biosanitaria, Ibs. Granada, Granada 18012, Spain

Cristina Jiménez-Luna, Octavio Caba, Institute of Biopathology and Regenerative Medicine (IBIMER), University of Granada, Granada 18016, Spain

Carlos García-Collado, Pharmacogenetics Unit, Virgen de las Nieves University Hospital, Granada 18014, Spain

Antonio Rodríguez-Fernández, Department of Medicina Nuclear, Virgen de las Nieves University Hospital, Granada 18014, Spain

Javier Luis López-Hidalgo, Department of Anatomía Patológica, Virgen de las Nieves University Hospital, Granada 18014, Spain

Author contributions: Martínez-Galán J collected and analyzed the data, took care of the patient and wrote and edited the manuscript; Rodriguez I, Maza E contributed to collect and analyze the patient data; García-Collado C contributed to the patient's treatment; Rodríguez-Fernández A contributed to the acquisition and analysis of pathologic images; López-Hidalgo JL contributed to molecular diagnostics; Jiménez-Luna C contributed to critical revision and writing of the manuscript; Caba O contributed to conceptualization and supervision; all authors have read and approved the final manuscript.

Informed consent statement: Informed written consent was obtained from the patient for publication of this report and any accompanying images.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

CARE Checklist (2016) statement: The authors have read CARE Checklist (2016), and the manuscript was prepared and revised according to CARE Checklist (2016).

Corresponding author: Cristina Jiménez-Luna, PhD, Senior Researcher, Institute of Biopathology and Regenerative Medicine (IBIMER), University of Granada, Avenida del Conocimiento, s/n, Granada 18016, Spain. crisjilu@ugr.es

Received: December 31, 2023
Peer-review started: December 31, 2023
First decision: January 27, 2024
Revised: February 9, 2024
Accepted: March 13, 2024
Article in press: March 13, 2024
Published online: May 15, 2024
Processing time: 129 Days and 20 Hours

Core Tip

Core Tip: The lack of specific symptoms in patients and the absence of a reliable and well-stablished diagnostic method, makes advanced pancreatic ductal adenocarcinoma (PDAC) the most common clinical appearance of pancreatic cancer cases. In these circumstances, surgical resection, the only curative approach for this malignancy, is unaffordable, leading to very low survival outcomes. Immunotherapy is a recent approach that has been studied in many cancer types showing encouraging results, but it has not been sufficiently investigated in PDAC. We report the case of a patient with unresectable PDAC that progressed to metastasis after treatment with chemoradiation, who showed an outstanding response to immunotherapy with pembrolizumab, achieving a complete remission within a few months, which was maintained until the end of treatment. Currently, the patient continues in disease-free state.